
Opinion|Videos|August 30, 2024
Insights on Conjugate Pneumococcal Vaccines
The vaccination experts analyze the impact of currently approved pneumococcal vaccines on otitis media prevention and compare the newer conjugate vaccines (PCV15 and PCV20) to their predecessors in terms of strain coverage and clinical efficacy.
Advertisement
Episodes in this series

- What effect do currently approved pneumococcal vaccines have on preventing otitis media?
- How do the newer conjugate vaccines (PCV15 and PCV20) compare to their predecessors in terms of strain coverage and clinical efficacy?
- What are your considerations for selecting between conjugate vaccines for adult patients who are vaccine-naïve?
- When would you use PCV20 instead of PCV15 and vice versa?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
The Biosimilar Conversation Nobody Is Having at the Pharmacy Counter: Why Adoption Is Still Struggling and What We Can Do About It
2
Medicare Is Finally Covering GLP-1s for Weight Loss: What the Bridge Program Means for Your Practice
3
FDA Narrows Compounding Rules for GLP-1s: How Pharmacists Should Respond
4
Closing the Gaps in Men’s Health Through MTM and Community Engagement
5

















































































































